Biomarkers

If correct, the paper points to a previously underappreciated immune cell (GzmK+ tissue-resident CD8+ T cells) as a potential driver of Crohn’s inflammation — which could lead to new biomarkers or therapies that work...

A reliable, accurate intestinal ultrasound could make routine monitoring easier, faster, and less costly than repeated MRI for people with Crohn’s disease. The study shows strong agreement between ultrasound scores and...

People with Crohn's disease often develop intestinal fibrosis and strictures that current drugs don't reverse; a growing drug pipeline aiming at anti‑fibrotic therapies could change future treatment options.

The study identifies colonic gene-expression programs that correlate with treatment failure, higher surgery rates, and perianal disease in Crohn’s — findings that could guide future prognostic tests and targeted...

This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.

Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.

The study suggests that clinical remission on biologics can hide ongoing gut microbiome, metabolite, and epithelial abnormalities that may influence flare risk. This matters because focusing only on immune suppression...

Environmental pollutants are increasingly linked to Crohn's disease risk, especially when exposures occur in early life. Understanding these links may help explain rising IBD rates and guide future prevention research.

Distinguishing Crohn’s from ulcerative colitis can be hard and often requires invasive tests. A reliable blood test would speed diagnosis and help patients start the right treatments sooner. This study is an early step...

Fatigue is a common, burdensome symptom in Crohn's disease and hard to treat. This study links fatigue severity to differences in brain resting-state connectivity, suggesting brain–gut interactions may play a role.

This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.

A biomarker that appears before inflammation could help detect Crohn’s disease earlier or predict relapses. Understanding early immune changes may point to new preventive strategies rather than only treating inflammation...

The findings point to an immune-cell change that may happen before Crohn’s symptoms appear, which could help predict relapse or guide future therapies. That could eventually affect monitoring or new treatment strategies...

This study identifies a specific immune cell (γδ intraepithelial lymphocytes) that may fail before Crohn’s disease appears, which could help researchers develop early biomarkers or new therapies to prevent inflammation.

Research that maps neutrophil behavior in children with Crohn’s could reveal biological mechanisms and biomarkers relevant to disease progression or treatment response. Understanding neutrophil roles helps scientists...

This study points to a possible microbiome biomarker (M. gnavus) tied to joint inflammation in people with Crohn’s disease, which could help explain why some patients develop arthritis and might eventually inform...

The study identifies a specific gut bacterium, Mediterraneibacter gnavus, that may act as a biomarker for joint inflammation in people with Crohn's disease. Understanding microbiome–immune links could eventually help...

This study suggests a microbiome‑based biomarker (IgG reactivity to certain gut bacteria, especially M. gnavus) could help identify spondyloarthritis in people with Crohn’s disease and distinguish axial from peripheral...

This project aims to develop wearable-based digital biomarkers to detect IBD flares earlier and make remote monitoring easier, which could help patients and clinicians manage disease more proactively. It describes...

The study points to a specific gut microbe, Mediterraneibacter gnavus, that may be linked to joint inflammation in people with Crohn's disease. If confirmed, a microbial biomarker could help identify who is at risk for...

Adaptive platform trials could speed testing of multiple Crohn’s treatments and make it easier to compare options, which may shorten the time to find effective therapies. The article outlines design choices and...

If metabolomic blood markers can reliably indicate IBD risk years before symptoms, researchers may better understand disease development and eventually design earlier detection or prevention strategies. For patients, the...

This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.

People with Crohn's disease who have an ileostomy need reliable, noninvasive tools to monitor for postoperative small-bowel inflammation. This study suggests fecal calprotectin measured from ileostomy output may help...

New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based...

Arthralgia and other extraintestinal symptoms may signal higher risk of developing peripheral arthritis in people with Crohn disease. Recognizing early joint pain could prompt closer monitoring or earlier rheumatology...

This reports Phase 2 clinical data for an oral TYK2 inhibitor (VTX958) in Crohn’s disease — a potential new oral treatment approach. The drug showed meaningful endoscopic improvements and reductions in inflammatory...

A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...

People with Crohn’s disease who have an ileostomy have limited noninvasive ways to monitor small-bowel inflammation. This study suggests measuring fecal calprotectin from ileostomy output could help detect postoperative...

A noninvasive wearable that tracks inflammation markers could let people with IBD and their clinicians detect rising disease activity earlier and potentially act before symptoms develop. This may make monitoring less...

Researchers are exploring whether gut microbes differ in patients who develop fibrous strictures — a common, surgery-prone complication of Crohn’s disease — because that could help predict risk or point to new prevention...

The study identifies a specific bacterial protein region (flagellin epitope) that many Crohn’s patients make antibodies to, which could help diagnose disease and predict who may develop complications.

The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...

This paper highlights potential ubiquitination-related genes and immune-cell patterns that could help researchers understand Crohn’s disease biology and point to new targets for lab validation. For patients, it signals...

A study aiming to identify who is likely to develop Crohn’s disease and to test preventing it could eventually allow truly early treatment before symptoms begin. If successful, validated biomarkers and a risk score could...

Researchers are trying to find blood biomarkers and a risk score that could predict who will develop Crohn’s disease before symptoms appear, which might enable earlier interventions or prevention in the future.

If successful, validated biomarkers and a blood risk score could allow clinicians to identify people at high risk of developing Crohn's disease and eventually test interventions to prevent symptoms. Prevention-focused...

This project aims to detect Crohn’s before symptoms appear and test preventive treatment—research that could change diagnosis and care for people with family risk. Successful biomarkers could allow earlier monitoring or...

This model aims to identify healthy first‑degree relatives at higher risk of developing Crohn’s disease before symptoms start, which could enable earlier monitoring or preventive strategies. The score uses simple...